Emergency care saves lives.18,400in the US alone.estimated new traumatic spinal cord injuries every year.NSCISC · Facts & Figures 2025 ↗
A lifetime of consequences. No cure for a severed spinal cord.15,400,000people living with spinal cord injury worldwide in 2021.WHO · Global SCI estimates ↗
Survival is not the finish lineMovement · Independence · Life, continued
01 / 06
Neural fusion as a complete therapy
A formulation alone is not a therapy. We are developing the tissue conditions, fusogen formulation, delivery protocol and recovery pathway as one coordinated approach.
Prepare the repair site
Preserve viable tissue, align the injured ends and establish the mechanical stability that repair requires.
Enable neural fusion
Develop an investigational PEG–chitosan fusogen formulation intended to support membrane repair and neural reconnection.
Coordinate delivery
Bring concentration, exposure, timing and treatment sequence into a protocol that can be tested and reproduced.
Track recovery
Follow function over time, coordinate rehabilitation and use recovery measurements to refine the whole therapy.
Neural reconnection · Experimental evidence
Severed spinal cords Restored movement
Following complete spinal cord transection, treated animals regained movement in both rabbit and swine studies. The experimental foundation spans rodents, rabbits, large animals and cadaveric procedures.
Movement alone is not enough. Functional scoring, microscopy and axonal tracing cross-check the result at three levels: what the body does, how the tissue connects and where the neural pathways lead.
Functional recovery
They walked
Neurological scores tracked recovery over 60 days. This sequence follows one treated animal walking at days 10, 21 and 40.
Random assignment, blinded neurological scoring, 60-day follow-up. All three treated pigs walked on four limbs; neither control walked independently. Ataxia persisted in treated animals.
Three complementary methods
Function, tissue morphology and axonal tracing were assessed within the same study. Tracing was performed in one treated animal. These are complementary readouts, not independent replications.
Scope of the evidence
The study evaluated local gel and systemic PEG with surgical stabilization and rehabilitation. These animal results do not establish human efficacy. Clinical contusion injuries require separate validation.
Kai Micah Mills
Thiel Fellow, founder of Cryopets, and co-founder of CryoDAO and HydraDAO. He builds organizations advancing cryopreservation, biological replacement and longevity research.
Michael Lebenstein-Gumovski
Neurosurgeon and researcher at the Sklifosovsky Institute. He has studied spinal cord injury since 2013, focusing on fusogen-based approaches to restoring neural continuity.
Andrei Panferov
Technology entrepreneur and AI builder. He turns complex, unsolved challenges into mathematical problems that computers can tackle — bringing that approach to the development of biological repair.
Eli Mohamad
Co-founder of CryoDAO, X-Therma and the Organ Preservation Alliance. He is also a founding ambassador of the American Biostasis Foundation.
Let's restore continuity together
Help move tissue repair from an early biological signal toward a reproducible therapy. We welcome scientific collaborators, specialist clinical teams and partners who build for the long term.
Investors
Supporting comparative studies and the work toward clinical translation.
Clinical partners
Surgical centers and teams to co-develop the operative protocol.
Researchers
Collaborators extending the preclinical and translational work.
Strategic collaborators
Industry and institutional partners advancing delivery and translation.
Neural injury
Surgical tissue joins
Vascular reconnection
Fibrotic healing
